Real-World Efficacy of Asciminib in Chronic Myeloid Leukemia After Multiple Tyrosine Kinase Inhibitors
Asciminib demonstrated real-world efficacy and tolerability among patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with tyrosine kinase inhibitors (TKIs), according to study results published in Clinical Lymphoma, Myeloma, & Leukemia.
The ABL/BCR::ABL1 inhibitor, asciminib, has been approved for patients with CML-CP who have been treated previously with 2 or more TKIs or have a T315I mutation. Researchers conducted a retrospective analysis to assess real-world efficacy of asciminib. Primary endpoints were time-to-treatment discontinuation and molecular response ([MR]; time-to-BCR::ABL ≤0.1% and time-to-BCR::ABL1 ≤1%).
Overall, 97 patients were included in the analysis and the median age among patients was 63 years. Included patients received either 2 (47.4%), 3 (24.7%), or more than 4 (27.8%) prior TKIs. At 12 weeks 85.7% of patients remained on asciminib. In terms of response, BCR::ABL1 ≤0.1% was achieved or maintained in 31.3% (95% confidence interval [CI], 21.6 to 43.9) of patients and 51.3% (95% CI, 40.1% to 63.6%) achieved BCR::ABL1 ≤1%. At 24 weeks, the number of patients still receiving treatment was 78.1%. Of which, BCR::ABL1 ≤0.1% was achieved or maintained by 49.7% (95% CI, 38.1 to 62.6) of patients and 64.2% (95% CI, 52.6 to 75.6) achieved or maintained BCR::ABL1 ≤1%.
“Results of this real-world study describing clinical outcomes among patients with CML-CP treated with asciminib after ≥2 prior TKIs in the US demonstrated that asciminib was well-tolerated and effective,” the researchers concluded, adding, “these findings were consistent with results from the ASCEMBL trial.”
Source:
Atallah EL, Wei D, Latremouille-Viau D, et al. Real-world evaluation of treatment patterns and clinical outcomes among patients with chronic myeloid leukemia in chronic phase treated with asciminib in clinical practice in the United States: Real-world asciminib treatment outcomes in CML-CP. Clinical Lymphoma, Myeloma and Leukemia. Published online September 26, 2024. doi: 10.1016/j.clml.2024.09.013
